June 2022
In both cases, the methods and uses become methods and uses for inhibiting angiogenesis, comprising contacting a tissue comprising, or a population of, angiogenic or potentially angiogenic blood vessels, i.e., those exposed to or potentially exposed to VEGF, with an anti-angiogenic composition comprising a biologically effective amount of at least a first VEGFR2-blocking, anti-VEGF antibody of the invention, or an antigen-binding fragment thereof, under conditions effective to inhibit angiogenesis
FDA alerted the public about Chinese weight-loss products, Chaso (Jianfei) Diet Capsules and Chaso Genpi, because they pose a potential public health risk
Humanas Q4 and recent partnerships : Humana saw its 2024 profit cut in half due to higher-than-expected medical costs in its Medicare Advantage plans
Researchers found that people on an intravenous drip of liraglutide ate 12% less at a lunch buffet, compared to people receiving a placebo